DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactEarnings

Mankind Pharma Limited — Other Restructuring

NSE 4d ago·26 Aug 2026, 11:14 am

Mankind Pharma

Mankind Pharma has approved the voluntary liquidation of Bharat Serums and Vaccines, a wholly-owned subsidiary. This strategic move will integrate Bharat Serums into Mankind's main operations.

This decision is significant as it aims to streamline the group's structure and improve overall efficiency. By consolidating operations, the company can focus its resources on its core strengths, which may benefit its long-term growth trajectory.

Investors should monitor how this integration impacts the company's financial performance and operational synergies in the coming quarters. The success of this restructuring will be a key factor in the stock's future performance.